Cd200r agonist antibodies and uses thereof

Abstract

The present invention relates to anti-human CD200R agonist antibodies, and uses thereof for treating diseases such as atopic dermatitis, chronic spontaneous urticaria, allergy, asthma, scleroderma, IBD, SLE, MS, RA, GvHD, or psoriasis.

We claim: 
     
         1 . An antibody comprising a heavy chain variable region (HCVR) and a light chain variable region (LCVR), wherein the HCVR comprises a HCDR1, HCDR2, and HCDR3, and the LCVR comprises a LCDR1, LCDR2, and LCDR3, wherein the amino acid sequence of the HCDR1 is given by SEQ ID NO: 1, the amino acid sequence of the HCDR2 is given by SEQ ID NO: 2, and the amino acid sequence of the HCDR3 is given by SEQ ID NO: 3, the amino acid sequence of the LCDR1 is given by SEQ ID NO: 4, the amino acid sequence of the LCDR2 is given by SEQ ID NO: 5, and the amino acid sequence of the LCDR3 is given by SEQ ID NO: 6, and wherein the antibody binds human CD200R. 
     
     
         2 . The antibody of  claim 1 , comprising a HCVR and a LCVR, wherein the amino acid sequence of the HCVR is given by SEQ ID NO: 7 and the amino acid sequence of the LCVR is given by SEQ ID NO: 8. 
     
     
         3 . The antibody of  claim 2 , wherein Xaa at position 1 of SEQ ID NO: 7 is glutamine. 
     
     
         4 . The antibody of  claim 2 , wherein Xaa at position 1 of SEQ ID NO: 7 is pyroglutamic acid. 
     
     
         5 . The antibody of  claim 2 , comprising a heavy chain (HC) and a light chain (LC), wherein the amino acid sequence of the HC is given by SEQ ID NO: 9 and the amino acid sequence of the LC is given by SEQ ID NO: 10. 
     
     
         6 . The antibody of  claim 5 , wherein Xaa at position 1 of SEQ ID NO: 9 is glutamine. 
     
     
         5 . The antibody of  claim 5 , wherein Xaa at position 446 of SEQ ID NO: 9 is glycine. 
     
     
         8 . The antibody of  claim 5 , wherein Xaa at position 1 of SEQ ID NO: 9 is glutamine and Xaa at position 446 of SEQ ID NO: 9 is glycine. 
     
     
         9 . The antibody of  claim 5 , wherein Xaa at position 1 of SEQ ID NO: 9 is glutamine and Xaa at position 446 of SEQ ID NO: 9 is absent. 
     
     
         10 . The antibody of  claim 5 , wherein Xaa at position 1 of SEQ ID NO: 9 is pyroglutamic acid and Xaa at position 446 of SEQ ID NO: 9 is absent. 
     
     
         11 . A method of treating a patient having a disease, wherein the disease is an autoimmune disease, allergic disease, asthma, atopic dermatitis, or other inflammatory disorders, comprising administering to the patient an effective amount of an antibody comprising a heavy chain variable region (HCVR) and a light chain variable region (LCVR), wherein the HCVR comprises a HCDR1, HCDR2, and HCDR3, and the LCVR comprises a LCDR1, LCDR2, and LCDR3, wherein the amino acid sequence of the HCDR1 is given by SEQ ID NO: 1, the amino acid sequence of the HCDR2 is given by SEQ ID NO: 2, and the amino acid sequence of the HCDR3 is given by SEQ ID NO: 3, the amino acid sequence of the LCDR1 is given by SEQ ID NO: 4, the amino acid sequence of the LCDR2 is given by SEQ ID NO: 5, and the amino acid sequence of the LCDR3 is given by SEQ ID NO: 6, and wherein the antibody binds human CD200R. 
     
     
         12 . The method of  claim 11  wherein the antibody comprises a heavy chain (HC) and a light chain (LC), wherein the amino acid sequence of the HC is given by SEQ ID NO: 9 and the amino acid sequence of the LC is given by SEQ ID NO: 10. 
     
     
         13 . A pharmaceutical composition comprising 1) an antibody comprising a heavy chain variable region (HCVR) and a light chain variable region (LCVR), wherein the HCVR comprises a HCDR1, HCDR2, and HCDR3, and the LCVR comprises a LCDR1, LCDR2, and LCDR3, wherein the amino acid sequence of the HCDR1 is given by SEQ ID NO: 1, the amino acid sequence of the HCDR2 is given by SEQ ID NO: 2, and the amino acid sequence of the HCDR3 is given by SEQ ID NO: 3, the amino acid sequence of the LCDR1 is given by SEQ ID NO: 4, the amino acid sequence of the LCDR2 is given by SEQ ID NO: 5, and the amino acid sequence of the LCDR3 is given by SEQ ID NO: 6, and 2) one or more pharmaceutically acceptable carriers, diluents, or excipients. 
     
     
         14 . The pharmaceutical composition of  claim 13  wherein the antibody comprises a heavy chain (HC) and a light chain (LC), wherein the amino acid sequence of the HC is given by SEQ ID NO: 9 and the amino acid sequence of the LC is given by SEQ ID NO: 10. 
     
     
         15 . The pharmaceutical composition of  claim 14  wherein Xaa at position 1 of SEQ ID NO: 9 is glutamine and Xaa at position 446 of SEQ ID NO: 9 is absent. 
     
     
         16 . The pharmaceutical composition of  claim 14 , wherein Xaa at position 1 of SEQ ID NO: 9 is pyroglutamic acid and Xaa at position 446 of SEQ ID NO: 9 is absent. 
     
     
         17 . A DNA molecule comprising a polynucleotide that encodes a HC whose amino acid sequence is given by SEQ ID NO: 9 or a polynucleotide that encodes a LC whose amino acid sequence is given by SEQ ID NO: 10. 
     
     
         18 . The DNA molecule of  claim 17 , in which the sequence of the polynucleotide that encodes the HC is given by SEQ ID NO: 12 or the sequence of the polynucleotide that encodes the LC is given by SEQ ID NO: 13. 
     
     
         19 . The DNA molecule of  claim 17  comprising 1) a polynucleotide that encodes the HC whose amino acid sequence is given by SEQ ID NO: 9, and 2) a polynucleotide that encodes the LC whose amino acid sequence is given by SEQ ID NO: 10. 
     
     
         20 . A mammalian cell transformed with the DNA molecule of  claim 19 , which transformed mammalian cell is capable of expressing an antibody comprising two HCs and two LCs, in which the amino acid sequence of each HC is given by SEQ ID NO: 9, and the amino acid sequence of each LC is given by SEQ ID NO: 10.